Triumpharma Information

Triumpharma, founded in 2002, is a full-service Contract Research Organization (CRO) that partners with pharmaceutical and biotech companies to bring innovative therapies to global markets. With expertise spanning Phase I–IV clinical trials, bioequivalence/bioavailability studies, and clinical data management, the company has managed over 300 regulatory submissions to agencies such as the US FDA, EMA, MHRA, and various MENA regulators. Its research covers a broad range of therapeutic areas—including cardiovascular, gastrointestinal, respiratory, metabolic, neurology, psychiatry, oncology, and more—along with early-phase and POC studies for conditions like asthma, NASH, Parkinson’s, AF, and diabetes. Triumpharma also has significant experience with monoclonal antibodies, biosimilars, and biotech products. The company’s capabilities are reinforced by advanced infrastructure and compliance with international quality standards. Triumpharma operates an 80-bed clinical facility (expandable to 200+ through hospital partnerships), a bioanalytical lab equipped with 5 LC/MS/MS machines, and in-house diagnostic labs. Its multidisciplinary team includes investigators, nurses, project managers, and data specialists, supported by secure clinical trial units and an IMP depot. Recognized for its regulatory excellence, Triumpharma has undergone successful inspections by leading authorities such as the FDA, EMA, and national health ministries across Europe and the Middle East. With over two decades of experience, it offers clients both robust infrastructure and a highly skilled team expert at delivering innovative study designs and regulatory strategies for clinical success.